W
WAVEMAN · COMPANY
MYO · Myomo, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

MYO

MYOMO, INC.
MEDICAL DEVICES · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · CIK 0001369290
CLUSTER · 3 INSIDERSFORM 144 · 3☆ WATCH
INSIDER NET · 180D
$242.8K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
3
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
50
13F, latest reported quarter
REVENUE GROWTH
+25.7%
XBRL, annual
NET MARGIN
-38.1%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$242.8K over 180 days
-$81.4K over 90 days
more than 86% of Medical Devices
CONGRESS
no member of Congress has reported trading it
FUNDS
50 funds added or opened last quarter
below 61% of Medical Devices
REVENUE
+25.7% year over year
more than 80% of Medical Devices
MARGIN
-38.1% net margin
below 69% of Medical Devices
BUYBACKS
no share repurchases reported
SHORT
4.7% of shares outstanding short · 5.6 days to cover · settled 2026-07-31
more than 60% of Medical Devices
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
3 insiders bought a net $242.8K, but 3 Form 144 notices ($57.1K) are queued to sell.
50 funds added or opened positions in the latest 13F quarter, of 80 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +35.8%
+35.8%12M
-40%-1%+37%+75%2025-092025-102025-122026-032026-052026-072026-09 2026-05-14 · Manko Joseph M. Jr. bought $146.9K2026-05-14 · Mitchell Micah sold $77.6K2026-03-13 · KIRK THOMAS F bought $51.1K2026-03-12 · Getz Heather C bought $51.1K2026-06-05 · KIRK THOMAS F bought $50.8K2026-05-18 · KIRK THOMAS F bought $39.5K2026-08-20 · Kovelman Harry sold $30.3K2026-08-20 · Kovelman Harry sold $29.9K2026-05-15 · KIRK THOMAS F bought $28.8K2026-05-15 · Manko Joseph M. Jr. bought $27.0K2026-05-28 · KIRK THOMAS F bought $24.8K2026-09-02 · Morris Milton Mayo sold $21.1K2026-05-27 · Kovelman Harry sold $20.5K2026-03-16 · Getz Heather C bought $14.0K2026-05-28 · Kovelman Harry sold $11.8K2025-11-20 · KIRK THOMAS F bought $3.5K2025-11-18 · Crowley Thomas Aloysius Jr. bought $2.9K2025-11-21 · KIRK THOMAS F bought $1.8K2025-11-19 · Crowley Thomas Aloysius Jr. bought $2962026-09-02 · Morris Milton Mayo filed to sell $21.1K2026-08-20 · HARRY KOVELMAN filed to sell $30.3K2026-07-13 · David Henry filed to sell $5.6K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
3 insiders reported buying shares.
The record shows a net $242.8K bought by insiders over 180 days, 50 funds added last quarter, $57.1K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
TMOPENROKBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDX
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, MYOMO, INC. insiders bought a net $242.8K of stock across 63 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Morris Milton Mayo
Director
SELL
2026-09-02
15,000.0
$21.1K
Kovelman Harry
Chief Medical Officer
SELL
2026-08-20
17,250.0
$29.9K
Kovelman Harry
Chief Medical Officer
SELL
2026-08-20
17,500.0
$30.3K
KIRK THOMAS F
Director
BUY
2026-06-05
40,002.0
$50.8K
KIRK THOMAS F
Director
BUY
2026-05-28
25,000.0
$24.8K
63 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 58 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Rosalind Advisors, Inc.
3,637,886.0 sh
$3.8M
VANGUARD CAPITAL MANAGEMENT LLC
1,636,570.0 sh
$1.7M
AQR CAPITAL MANAGEMENT LLC
928,268.0 sh
$965.4K
Jefferies Financial Group Inc.
704,275.0 sh
$732.4K
JANE STREET GROUP, LLC
596,352.0 sh
$620.2K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Morris Milton Mayo
FILED 2026-09-02
$21.1K
HARRY KOVELMAN
FILED 2026-08-20
$30.3K
David Henry
FILED 2026-07-13
$5.6K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
iShares Micro-Cap ETF
$67.2K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$4.6K POSITION · AS OF 2026-03-31
0.0%
Fidelity Small Cap Growth Index Fund
$18.8K POSITION · AS OF 2026-03-31
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$23.8K POSITION · AS OF 2026-02-28
0.0%
iShares Russell 2000 Growth ETF
$180.8K POSITION · AS OF 2026-03-31
0.0%
Penn Series Small Cap Index Fund
$878 POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 2 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
2
Not applicable
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$1.2M
-$348.6K
$649.0K
+78%
—
2024
$1.2M
$1.5M
$739.6K
+1159%
—
2023
$663.9K
$2.1M
$478.6K
+880%
—
2022
$526.0K
$179.6K
$352.9K
-93%
—
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$40.9M$32.6M$19.2M$15.6M
GROSS PROFIT$26.9M$23.2M$13.2M$10.3M
OPERATING INCOME$-14.4M$-6.2M$-8.2M$-10.7M
NET INCOME$-15.6M$-6.2M$-8.1M$-10.7M
EPS (DILUTED)-0.37-0.16-0.28-1.52
OPERATING CASH FLOW$-14.5M$-3.3M$-6.2M$-10.2M
CASH$14.1M$24.4M$6.9M$5.3M
LONG-TERM DEBT$11.2M$0——
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →